Drugs / [18F]MNI-952
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03080051 | Aug 2016 → Mar 2017 | Alzheimer disease, progressive supranuclear palsy | Molecular NeuroImaging | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MNI-952 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03080051 ↗ |
| Known as | [18F]UCB-K | “\[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.” NCT03080051 ↗ |
| Modality | Diagnostic / imaging agent | “a tau targeted PET radioligand” NCT03080051 ↗ |